Targeted drug delivery for the treatment of blood cancers

Journal article : Review

Abstract:: Blood cancers are a type of liquid tumor which means cancer is present in the body fluid. Multiple myeloma, leukemia, and lymphoma are the three common types of blood cancers. Chemotherapy is the major therapy of blood cancers by systemic administration of anticancer agents into the blood. However, a high incidence of relapse often happens, due to the low efficiency of the anticancer agents that accumulate in the tumor site, and therefore lead to a low survival rate of patients. This indicates an urgent need for a targeted drug delivery system to improve the safety and efficacy of therapeutics for blood cancers. In this review, we describe the current targeting strategies for blood cancers and recently investigated and approved drug delivery system formulations for blood cancers. In addition, we also discuss current challenges in the application of drug delivery systems for treating blood cancers.

Files:: Jiang_et_al_2022_Targeted_drug_delivery.pdf

(Preview, Version of record, pdf, 12.5MB, Terms of use)

Language:: English
Keywords:: antineoplastic combined chemotherapy protocols

drug compounding

drug carriers

disease management

antineoplastic agents

drug delivery systems

molecular targeted therapy

theranostic nanomedicine

tumor biomarkers

disease susceptibility

FFR

treatment outcome

hematologic neoplasms
Subtype:: Review
Pubs id:: 1240588
Local pid:: pubs:1240588
Deposit date:: 2024-01-10
ARK identifier:: ark:/29072/ora_6612b31099cc4e1d8fa35abe6226c321

Copyright holder:: Jiang et al.
Rights statement:: Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

If you are the owner of this record, you can report an update to it here: Report update to this record